Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Ma, Xingqun ^a   Yao, Yanwen ^a   Yuan, Dongmei ^a   Liu, Hongbing ^a   Wang, Shouju ^a   Zhou, Changsheng ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RECOMBINANT ENDOSTATIN; SODIUM CHLORIDE; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; LEWIS CARCINOMA; LOW DRUG DOSE; LYMPHANGIOGENESIS; MALE; MALIGNANT PLEURA EFFUSION; MICROCIRCULATION; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA FLUID; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENDOSTATINS; GREEN FLUORESCENT PROTEINS; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL EFFUSION, MALIGNANT; RECOMBINANT PROTEINS;

MUS;

EID: 84871694456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053449     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Lee YC, Light RW, (2004) Management of malignant pleural effusions. Respirology 9: 148-156.
3. Kaifi JT, Toth JW, Gusani NJ, Kimchi ET, Staveley-O'Carroll KF, et al. (2012) Multidisciplinary management of malignant pleural effusion. J Surg Oncol 105: 731-738.
4. Jantz MA, Antony VB, (2008) Pathophysiology of the pleura. Respiration 75: 121-133.
5. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, et al. (2001) Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7: 3366-3374.
6. Chernow B, Sahn SA, (1977) Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 63: 695-702.
7. Lynch TJ Jr, (1993) Management of malignant pleural effusions. Chest 103: 385S-389S.
8. Nagahashi M, Ramachandran S, Rashid OM, Takabe K, (2010) Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol 16: 4003-4012.
9. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
10. Brideau G, Makinen MJ, Elamaa H, Tu H, Nilsson G, et al. (2007) Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67: 11528-11535.
11. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S, (2005) Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22: 31-38.
12. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, et al. (2007) Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 29: 761-769.
13. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, et al. (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772-3784.
14. Ling Y, Yang Y, Lu N, You QD, Wang S, et al. (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84.
15. Ma X, Sun Y, Wang S, Yang Z, Song Y, (2012) [Establishment of a malignant pleural effusion mouse model with Lewis lung carcinoma cell lines expressing enhanced green fluorescent protein]. Zhongguo Fei Ai Za Zhi 15: 317-323.
16. Dong X, Zhao X, Xiao T, Tian H, Yun C, (2011) Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg 59: 133-136.
17. Fang F, Chen P, Wu X, Yang L, Yang X, et al. (2009) Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion. J Cancer Res Clin Oncol 135: 1149-1157.
18. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, et al. (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14: 1242-1251.
19. Wei HM, Qin SK, Yin XJ, Chen YL, (2010) [Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice]. Nan Fang Yi Ke Da Xue Xue Bao 30: 1509-1513.
20. Wei S, Sun Y, Yang Z, Song Y, (2010) [Establishment of orthotopic lung cancer model expressing enhanced green fluorescent protein]. Zhongguo Fei Ai Za Zhi 13: 670-675.
21. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, et al. (2006) Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34: 142-150.
22. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, et al. (2007) Prognostic significance of vascular endothelial cell growth factors-A,-C and-D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96: 1092-1100.
23. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
24. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, et al. (2006) Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24: 228-240.
25. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, et al. (2007) Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 67: 9825-9834.
26. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, et al. (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11: 373-382.
27. Gerber HP, Ferrara N, (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680.
28. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599.
29. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, et al. (2002) The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16: 1802-1804.
30. Lohela M, Bry M, Tammela T, Alitalo K, (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
31. Avraamides CJ, Garmy-Susini B, Varner JA, (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
32. Shibuya M, Claesson-Welsh L, (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560.
33. Reck M, Crino L, (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63: 1-9.